NOT FOR DISTRIBUTION
Header cover image

Market Cap

Rp6.9t

Last Updated

2021/05/10 17:09 UTC

Data Sources

Company Financials

Executive Summary

PT Indofarma (Persero) Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia. More Details


Snowflake Analysis

Questionable track record with imperfect balance sheet.


Similar Companies

Share Price & News

How has Indofarma (Persero)'s share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: INAF is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: INAF's weekly volatility has decreased from 13% to 7% over the past year.


Market Performance


7 Day Return

0.9%

INAF

1.3%

ID Pharmaceuticals

-0.5%

ID Market


1 Year Return

111.3%

INAF

20.4%

ID Pharmaceuticals

22.3%

ID Market

Return vs Industry: INAF exceeded the ID Pharmaceuticals industry which returned 20.4% over the past year.

Return vs Market: INAF exceeded the ID Market which returned 22.3% over the past year.


Shareholder returns

INAFIndustryMarket
7 Day0.9%1.3%-0.5%
30 Day-8.9%-3.8%-2.7%
90 Day-30.4%-9.1%-5.5%
1 Year111.3%111.3%22.7%20.4%26.3%22.3%
3 Year-47.9%-47.9%2.3%-3.3%2.3%-5.4%
5 Year135.8%135.8%32.9%20.3%34.1%17.8%

Long-Term Price Volatility Vs. Market

How volatile is Indofarma (Persero)'s share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Indofarma (Persero) undervalued compared to its fair value and its price relative to the market?

290.1x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: INAF (IDR2240) is trading above our estimate of fair value (IDR1356.56)

Significantly Below Fair Value: INAF is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: INAF is poor value based on its PE Ratio (290.1x) compared to the ID Pharmaceuticals industry average (25x).

PE vs Market: INAF is poor value based on its PE Ratio (290.1x) compared to the ID market (22.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INAF's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INAF is overvalued based on its PB Ratio (14.3x) compared to the ID Pharmaceuticals industry average (2.4x).


Future Growth

How is Indofarma (Persero) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Indofarma (Persero) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Indofarma (Persero) performed over the past 5 years?

9.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INAF has high quality earnings.

Growing Profit Margin: INAF's current net profit margins (0%) are lower than last year (0.6%).


Past Earnings Growth Analysis

Earnings Trend: INAF has become profitable over the past 5 years, growing earnings by 9.5% per year.

Accelerating Growth: INAF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: INAF had negative earnings growth (-99.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9%).


Return on Equity

High ROE: INAF's Return on Equity (0.01%) is considered low.


Financial Health

How is Indofarma (Persero)'s financial position?


Financial Position Analysis

Short Term Liabilities: INAF's short term assets (IDR1,134.7B) exceed its short term liabilities (IDR836.8B).

Long Term Liabilities: INAF's short term assets (IDR1,134.7B) exceed its long term liabilities (IDR446.3B).


Debt to Equity History and Analysis

Debt Level: INAF's debt to equity ratio (105.2%) is considered high.

Reducing Debt: INAF's debt to equity ratio has increased from 51.3% to 105.2% over the past 5 years.

Debt Coverage: INAF's debt is not well covered by operating cash flow (10.3%).

Interest Coverage: INAF's interest payments on its debt are not well covered by EBIT (1.4x coverage).


Balance Sheet


Dividend

What is Indofarma (Persero) current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INAF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INAF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INAF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INAF's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: INAF is not paying a notable dividend for the ID market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INAF's dividend in 3 years as they are not forecast to pay a notable one for the ID market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Arief Pramuhanto (58 yo)

2yrs

Tenure

Mr. Arief Pramuhanto has been President Director of PT Indofarma (Persero) Tbk since May 7, 2019. Mr. Pramuhanto was General Affairs and Human Capital Director at PT Kimia Farma (Persero) Tbk since April 2...


Leadership Team

Experienced Management: INAF's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: INAF's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Indofarma (Persero) Tbk's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PT Indofarma (Persero) Tbk
  • Ticker: INAF
  • Exchange: IDX
  • Founded: 1918
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Rp6.942t
  • Shares outstanding: 3.10b
  • Website: https://www.indofarma.id

Number of Employees


Location

  • PT Indofarma (Persero) Tbk
  • Jalan Indofarma No. 1
  • Cikarang Barat
  • Bekasi
  • Jawa Barat
  • 17530
  • Indonesia

Listings


Biography

PT Indofarma (Persero) Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia. The company manufactures, trades in, and distributes medicine and medical devices;...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/10 17:09
End of Day Share Price2021/05/10 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.